Knight Therapeutics (KHTRF) 6.5600 $KHTRF
Knight Therapeutics Inc.: In the Beginning of a Genesys Partnership
Marketwire Canada - Tue Aug 16, 7:03AM CDT
MONTREAL, QUEBEC--(Marketwired - Aug 16, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that it has committed to invest $1 million in the Genesys Ventures III LP ("Genesys Fund"

, a Canadian-based life sciences venture capital fund managed by Genesys Capital Management, Inc.
GUD.TO: 8.44 (+0.06)
Knight Medison Relationship Continues to Pay Dividends
Marketwire Canada - Mon Aug 15, 7:02AM CDT
MONTREAL, QUEBEC--(Marketwired - Aug 15, 2016) - Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries ("Knight"

, announced today receipt of an ILS 7.1 million [$2.4 million] dividend from Medison Biotech (1995) Ltd. ("Medison"

. Knight owns 28.3% of Medison, Israel's fourth largest specialty pharma company ranked by revenue. Knight has received two dividends from Medison year-to-date totalling ILS 14.2 million [$4.8 million]. Historically, Medison has declared dividends on a semi-annual basis.
GUD.TO: 8.44 (+0.06)
Knight Lends a Second Hand to Bloom Burton Debt Fund
Marketwired - Fri Aug 12, 7:01AM CDT
MONTREAL, QUEBEC--(Marketwired - Aug 12, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that it has invested $1 million in the Bloom Burton Healthcare Lending Trust II (the "Trust"

managed by Stratigis Capital Advisors Inc. as part of a minimum $5 million private placement. The Trust will use the proceeds to invest in debt and debt-like securities of emerging commercial-stage public and private Canadian healthcare companies that have been overlooked by traditional lenders. In July 2015, Knight invested $500,000 in the Trust's predecessor, the Bloom Burton Healthcare Lending Trust, which has performed well to date.
GUD.TO: 8.44 (+0.06)
Knight Reports Second Quarter 2016 Results
Marketwire Canada - Thu Aug 11, 5:01AM CDT
MONTREAL, QUEBEC--(Marketwired - Aug 11, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"

, a leading Canadian specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2016.
GUD.TO: 8.44 (+0.06)
Knight Therapeutics Inc. Announces Election of Directors
Marketwire Canada - Thu Jun 16, 5:01PM CDT
MONTREAL, QUEBEC--(Marketwired - Jun 16, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"

announced today that each director nominee listed in the Management Information Circular dated May 13, 2016 was elected as Director of the Company during the Annual Meeting of the Shareholders held in Montréal, Québec.
GUD.TO: 8.44 (+0.06)
Long Zone Holdings Announces Acquisition of Knight Therapeutics Inc. Common Shares
Marketwired - Thu Jun 02, 5:31PM CDT
MONTREAL, QUEBEC--(Marketwired - Jun 2, 2016) - Long Zone Holdings Inc. ("the Corporation"

announced that pursuant to a previously announced prospectus offering ("the Offering"

by Knight Therapeutics Inc. ("Knight"

, it has today acquired ownership of 45,000 common shares of Knight ("the Acquired Shares"

representing approximately 0.03% of the outstanding common shares of Knight. The Acquired Shares were acquired at a price of $8.00 per common share for an aggregate consideration of $360,000.
Knight to Present at Both the National Bank Financial Quebec Conference in Montreal and the Jefferies Healthcare Conference in New York City
Marketwired - Tue May 31, 7:01AM CDT
MONTREAL, QUEBEC--(Marketwired - May 31, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, President and CEO, is scheduled to present at the National Bank Financial Quebec Conference on Wednesday, June 1, 2016 at 2:00 pm ET at the Hotel Le Crystal in Montreal, while Jeffrey Kadanoff, CFO, is scheduled to present a corporate update at the Jefferies Healthcare Conference on Thursday, June 9, 2016 at 9:30 am ET at the Grand Hyatt New York. A copy of the Jefferies Healthcare Conference presentation will be available at www.gud-knight.com.
GUD.TO: 8.44 (+0.06)
Knight Reports First Quarter 2016 Results
Marketwire Canada - Tue May 10, 5:01AM CDT
MONTREAL, CANADA--(Marketwired - May 10, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"

, a leading Canadian specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2016. In thousands of Canadian dollars except for share and per share amounts.
GUD.TO: 8.44 (+0.06)
Knight Finds EMPAthetic Partner for Neuragen(R) in the Middle East
Marketwired - Mon Apr 25, 7:02AM CDT
Knight Therapeutics Inc. (TSX: GUD), through one of its wholly-owned subsidiaries ("Knight"

, announced today that it has entered into an exclusive distribution agreement with EMPA Healthcare LLC ("EMPA"

to commercialize Neuragen(R), a topical natural health product used to relieve the symptoms of peripheral nerve pain, in the United Arab Emirates and Kuwait. EMPA will also have non-exclusive distribution rights in the other Gulf Cooperation Council ("GCC"

countries. Knight may extend exclusivity on a country-by-country basis should certain minimum sales targets be met in each GCC country. Knight sold the rights to Neuragen(R) in the U.S. in June 2015 and retains the rights for all other territories.
GUD.TO: 8.44 (+0.06)
Knight Receives NOD from Health Canada for ATryn(R)
Marketwired - Mon Apr 25, 7:02AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, today announced that it has received a Notice of Deficiency ("NOD"

for its ATryn(R) New Drug Submission.
GUD.TO: 8.44 (+0.06)
Knight Blooms at Healthcare Investor Conference in Toronto
Marketwired - Mon Apr 25, 7:02AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that Mr. Jonathan Ross Goodman, President and CEO, and Mr. Jeffrey Kadanoff, CFO, are scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2016 at 1:30 pm ET at the Sheraton Centre Toronto Hotel. A copy of the presentation will be available at www.gud-knight.com.
GUD.TO: 8.44 (+0.06)